Abstract
Interest in the potential therapeutic benefits of psychedelic agents has recently increased. In addition to psilocybin, a wide variety of agents with psychedelic properties have been proposed and partially tested. However, the challenges of obtaining approval to market a restricted psychotomimetic agent are formidable.
Sellers, E. M., & Leiderman, D. B. (2017). Psychedelic Drugs as Therapeutics: No Illusions About the Challenges. Clinical Pharmacology & Therapeutics. 10.1002/cpt.776
Link to full text
Sellers, E. M., & Leiderman, D. B. (2017). Psychedelic Drugs as Therapeutics: No Illusions About the Challenges. Clinical Pharmacology & Therapeutics. 10.1002/cpt.776
Link to full text
